Last $7.45 USD
Change Today -0.13 / -1.72%
Volume 3.6K
ARDM On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

aradigm corp (ARDM) Snapshot

Open
$7.53
Previous Close
$7.58
Day High
$7.53
Day Low
$7.45
52 Week High
03/11/14 - $15.96
52 Week Low
11/18/14 - $6.43
Market Cap
109.7M
Average Volume 10 Days
65.2K
EPS TTM
$0.07
Shares Outstanding
14.7M
EX-Date
--
P/E TM
107.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for ARADIGM CORP (ARDM)

Related News

No related news articles were found.

aradigm corp (ARDM) Related Businessweek News

No Related Businessweek News Found

aradigm corp (ARDM) Details

Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of drugs delivered by inhalation for the treatment and prevention of respiratory diseases by pulmonologists. The company’s lead development candidates include Pulmaquin (ARD-3150) and Lipoquin (ARD-3100), which completed Phase IIb clinical trials for the management of infections associated with the severe respiratory diseases, such as non-cystic fibrosis bronchiectasis (BE) and cystic fibrosis (CF). Its products under development also comprise ARD-1100, a liposomal ciprofloxacin for the treatment of inhalation anthrax and other biodefense purposes; and ARD-1600, an inhaled nicotine product for smoking cessation. The company has a collaboration agreement with Oregon State University. Aradigm Corporation was founded in 1991 and is headquartered in Hayward, California.

12 Employees
Last Reported Date: 05/16/14
Founded in 1991

aradigm corp (ARDM) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $380.0K
Chief Financial Officer, Vice President of Fi...
Total Annual Compensation: $263.8K
Chief Medical Officer
Total Annual Compensation: $56.8K
Compensation as of Fiscal Year 2013.

aradigm corp (ARDM) Key Developments

Aradigm Corporation Presents at 7th annual Biotech Showcase Conference 2015, Jan-14-2015 02:30 PM

Aradigm Corporation Presents at 7th annual Biotech Showcase Conference 2015, Jan-14-2015 02:30 PM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States. Speakers: Igor Gonda, Chief Executive Officer, President and Executive Director.

Aradigm Corporation Presents at Stifel Healthcare Conference 2014, Nov-18-2014 08:00 AM

Aradigm Corporation Presents at Stifel Healthcare Conference 2014, Nov-18-2014 08:00 AM. Venue: The Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Igor Gonda, Chief Executive Officer, President and Executive Director.

Aradigm Corporation Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Aradigm Corporation announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenue was approximately $6.6 million compared with revenue of approximately $4.6 million for the third quarter of 2013. Revenue for both periods consisted primarily of revenue from the Grifols collaboration arrangement as the company is being reimbursed for Pulmaquin(R) inhaled ciprofloxacin project-related costs. Net loss was approximately $0.9 million, or $0.06 per basic and diluted share, compared with a net loss of approximately $14.9 million, or $1.59 per basic and diluted share, for the third quarter of 2013. The net loss in 2013 resulted primarily from the one-time, non-cash collaboration arrangement acquisition cost associated with the Grifols collaboration agreement. Loss from operations was $877,000 compared to $14,454,000 for the same period a year ago. For the nine months, the company reported total revenue was $25,493,000 compared to $5,079,000 for the same period a year ago. Loss from operations was $3,046,000 compared to $19,686,000 for the same period a year ago. Net income was $5,483,000 or $0.37 per basic and diluted share compared to net loss of $20,909,000 or $2.87 per basic and diluted share for the same period a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARDM:US $7.45 USD -0.13

ARDM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alexza Pharmaceuticals Inc $2.12 USD -0.098
Alkermes PLC $72.25 USD +0.06
Bayer AG €127.81 EUR -1.75
Gilead Sciences Inc $104.83 USD +0.65
GlaxoSmithKline PLC 1,467 GBp -25.50
View Industry Companies
 

Industry Analysis

ARDM

Industry Average

Valuation ARDM Industry Range
Price/Earnings 23.1x
Price/Sales 3.7x
Price/Book 2.8x
Price/Cash Flow 23.1x
TEV/Sales 2.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARADIGM CORP, please visit www.aradigm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.